Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
复制标题
DOI：
10.2147/ott.s198421
复制
发表时间：
2019-01-01
影响因子：
4
通讯作者：
Saito, Naoto
中科院分区：
文献类型：
--
作者：
Yoshida, Kazushige;Okamoto, Masanori;Saito, Naoto
目的：虽然抗pd -1抗体和使用抗pd - l1抗体治疗目前都在临床使用，但其治疗效果因癌症类型而异。造成这种差异的因素之一是不同癌症类型的免疫检查点分子的表达水平不同；因此，阐明所有类型人类癌症的临床结果与免疫检查点分子之间的关系是很重要的。本研究的目的是评估骨肉瘤的临床结果与PD-L1、PRF、GZMB和IFN γ表达的关系。方法：选取19例骨肉瘤临床标本，检测PD-L1、PRF、GZMB、IFN的表达。和他们的临床结果有关。结果：骨肉瘤临床标本中PD-L1表达与早期转移形成相关，PRF、GZMB等T细胞功能标志物高表达组总生存时间较长。结论：本研究首次阐明了骨肉瘤的临床结果与PD-L1、PRF、GZMB和IFN γ表达的关系。本研究为抗pd -1抗体治疗骨肉瘤的临床适应症和疗效预测提供了有价值的信息。
Purpose: Although both anti-PD-1 antibody and treatments using anti-PD-L1 antibody are currently in clinical use, their therapeutic effects vary according to cancer type. One of the factors accounting for this variability is the expression level of the immune checkpoint molecule that differs between cancer types; thus, it is important to clarify the relationship between clinical outcomes and immune checkpoint molecules for all types of human cancer. The purpose of this study is to evaluate the clinical outcome of osteosarcoma in relation to PD-L1, PRF, GZMB, and IFN gamma expression.Methods: Using 19 clinical specimens of osteosarcoma, we examined the expression of PD-L1, PRF, GZMB, and IFN. in relation to their clinical outcomes.Results: PD-L1 expression correlated with early metastatic formation in clinical specimens of osteosarcoma, and the group with highly expressed functional markers for T cells such as PRF and GZMB resulted in a long overall survival time.Conclusion: This is the first study to elucidate the clinical outcomes of osteosarcoma in relation to PD-L1, PRF, GZMB, and IFN gamma expression. This study provides valuable information regarding the clinical indication and prediction of effect for anti-PD-1 antibody in osteosarcoma.